News
Displaying 1–10 of 569
-
Recording Available: Insights Forum | Wednesday, June 24, 2026
Foundation NewsThe Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the blinding diseases community. The call took place on June 24, 2026.
-
Foundation News
This two-day golf tournament at Sanctuary Golf Course will help accelerate research toward treatments and cures for blinding diseases.
-
Potential Oral Stargardt Treatment Advances to Phase 3 Clinical Trial
Research NewsPromising oral treatment moves closer for Stargardt patients.
-
A Race Against Blindness Commits $1 Million to Advance Gene-Agnostic Therapeutic Approaches
Foundation NewsThe commitment directs $775,000 to the RD Fund, to be matched dollar for dollar, and $225,000 to a Foundation Fighting Blindness research award, advancing approaches that can help patients regardless of the gene causing their retinal disease
-
Research News
2020 Llura Liggett Gund Award recipient honored for pioneering gene therapy that transformed vision research.
-
Foundation News
The award recognizes Dr. Pierce’s contributions to inherited retinal disease research, including work that led to the first FDA-approved gene therapy for an inherited disease and leadership of the world’s first in vivo CRISPR genome-editing study in humans.
-
In the Press
Four-year cohort will enroll participants with inherited retinal diseases caused by mutations in the RHO gene. Study is intended to deepen understanding of disease progression and inform future clinical trial design in rhodopsin-associated retinal disease.
-
Atsena Therapeutics Advances to Pivotal Phase 3 Trial for X-Linked Retinoschisis
Research NewsData monitoring committee recommends proceeding with registration-enabling study for ATSN-201
-
Foundation News
The gathering will be held June 12–13 and will convene global communities impacted by blinding diseases, alongside researchers, clinicians, patient advocates, and industry partners to foster collaboration, innovation, and hope.
-
MeiraGTx Acquires XLRP Gene Therapy Bota-Vec, Moves Toward Regulatory Filing
Research NewsMeiraGTx has acquired bota-vec, a gene therapy for X-linked retinitis pigmentosa (XLRP), and plans to file for regulatory approval in the U.S., Europe, and Japan, with a potential launch in 2027.
